Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.41 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17529701 | 0.91 | TAAR1 (0.44) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL6700193 | 0.89 | TAAR1 (0.40) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15656642 | 0.81 | TAAR1 (0.44) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9453231 | 0.76 | TAAR1 (0.44) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19035442 | 0.76 | SIGMAR1 (0.50) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15657558 | 0.73 | TP53 (0.44) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15285895 | 0.73 | TAAR1 (0.41) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL6702760 | 0.71 | TP53 (0.42) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29033707 | 0.71 | TAAR1 (0.42) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL8601709 | 0.70 | TSHR (0.46) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774265-B2 | SALT FORMATION REACTION OF PHOSPHINE AND SECONDARY PHOSPHINE IN ALCOHOLIC SOLVENT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20040138504-A1 | BISPHOSPHONIUM SALT AND PROCESS FOR PRODUCING THE SAME | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138504-A1 | BISPHOSPHONIUM SALT AND PROCESS FOR PRODUCING THE SAME | PIP5K1B, PIP5K1A, PHOSPHO1 | SIGMAR1 1266/4885SLC6A2 3633/4885SLC6A4 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.